| |
Hypomagnesemic
group (n: 26) |
Normomagnesemic
group (n=42) |
P value |
| Age (year) |
36.3 ± 9.3 |
39.2 ± 10.9 |
0.268 |
| Gender (male/female) |
19/7 |
32/10 |
0.495 |
| Source of allograft (living/deceased) |
15/11 |
29/13 |
0.244 |
| Body mass index (kg/m2) |
27.0 ± 4.8 |
25.0 ± 3.4 |
0.070 |
| Follow-up duration after transplantation (mo) |
9.5 (1-132) |
46.5 (1-252) |
0.001 |
| Use of ACEI or ARB |
9 (34.6%) |
12 (28.6%) |
0.397 |
| Use of vitamin D |
9 (34.6%) |
11 (26.2%) |
0.318 |
| Systolic blood pressure (mmHg) |
134 ± 18 |
125 ± 15 |
0.026 |
| Diastolic blood pressure (mmHg) |
93 ± 13 |
85 ± 14 |
0.018 |
| Presence of post-transplant diabetes mellitus |
3 (11.5%) |
5 (11.9%) |
0.641 |
| Presence of post-transplant hypertension |
21 (80.8%) |
35 (83.3) |
0.516 |
| History of acute allograft rejection |
- |
10 (23.8%) |
0.005 |
| Serum magnesium (mEq/L) |
1.21 ± 0.12 |
1.68 ± 0.48 |
0.001 |
| Serum sodium (mEq/L) |
137.5 ± 2.9 |
137.4 ± 4.0 |
0.861 |
| Serum potassium (mEq/L) |
4.1 ± 0.4 |
4.2 ± 0.4 |
0.418 |
| Serum calcium (mg/dL) |
9.7 ± 0.5 |
8.4 ± 0.5 |
0.029 |
| Serum phosphorus (mg/dL) |
3.0 ± 1.0 |
3.3 ± 0.8 |
0.271 |
| Serum uric acid (mg/dL) |
6.5 ± 1.5 |
6.8 ± 1.5 |
0.321 |
| Alkaline phosphatase (IU/L) |
84 (40-169) |
81.5 (36-535) |
0.700 |
| Serum glucose (mg/dL) |
107.3 ± 19.1 |
95.8 ± 16.1 |
0.010 |
| Serum albumin (g/dL) |
4.1 ± 0.4 |
3.9 ± 0.5 |
0.194 |
| Hemoglobin (g/dL) |
14.0 ± 1.8 |
13.5 ± 1.9 |
0.260 |
| Intact parathormon (pg/mL) |
65 (13-532) |
83 (5-834) |
0.253 |
| Fractional excretion of sodium (%) |
1.3 (0.5-3.0) |
1.5 (0.5-5.5) |
0.303 |
| Fractional excretion of magnesium (%) |
6.5 ± 2.5 |
7.1 ± 4.4 |
0.492 |
| Creatinine clearance (mL/min) |
79.3 ± 30.0 |
58.3 ± 24.2 |
0.002 |
| Amount of proteinuria (mg/d) |
55 (0-1130) |
125 (0-1880) |
0.322 |
| Amount of 24-h urine volume (mL) |
3416 ± 1078 |
3450 ± 1207 |
0.908 |
ACEI: Angiotensin Converting Enzyme Inhibitor; ARB: Angiotensin II Receptor
Blocker